News

Filter

Current filters:

Lexapro

1 to 9 of 95 results

Forest Labs' profit slumps 76% on Lexapro patent loss

23-04-2013

US drugmaker Forest Laboratories (NYSE: FRX) posted fiscal fourth-quarter (ended March 31, 2013) profit…

FinancialForest LaboratoriesLexaproPharmaceutical

Forest Lab's earnings plunge 79%, hit by generic Lexapro

18-07-2012

US drugmaker Forest Laboratories (Nasdaq: FRX) yesterday reported that net income for the quarter ended…

FinancialForest LaboratoriesLexaproPharmaceutical

Forest Labs cuts FY 2013 earnings forecasts on Lexapro woes

12-06-2012

Following the expiration of US drugmaker Forest Laboratories' (NYSE: FRX) once best-selling anxiety drug…

FinancialForest LaboratoriesGenericsLevothroidLexaproPharmaceutical

Generic competition for Lexapro/Cipralex hits Lundbeck's first-quarter

02-05-2012

Danish drugmaker Lundbeck (LUND: DC) yesterday posted a 33% plunge in first-quarter 2012 net profit to…

CipralexFinancialLexaproLundbeckPharmaceutical

Forest Labs, Gedeon Richter plan 2012 filing for cariprazine

29-02-2012

Positive results from two phase III trials of Forest Laboratories and Gedeon Richter's new antipsychotic…

cariprazineForest LaboratoriesGedeon RichterHomeLexaproNamendaNeurologicalPharmaceutical

Changing the mood of Brazilian antidepressant market; fake Levitra

24-08-2011

The Vice President of Brazil’s Superior Court of Justice (STJ), Minister Felix Fischer, has restored…

BayerGenericsLevitraLexaproLundbeckNeurologicalPharmaceuticalRegulationReproductiveSouth America

Forest Labs extends tender offer to acquire Clinical Data

06-04-2011

Forest Laboratories, Inc. (NYSE: FRX) says that it has extended the expiration date of its tender offer…

Clinical DataForest LaboratoriesLexaproMergers & AcquisitionsNeurologicalPharmaceuticalViibryd

1 to 9 of 95 results

COMPANY SPOTLIGHT

Menarini

Back to top